Dyno to receive a $15 million fee plus potential milestone and royalty payments under terms established in the companies' 2021 research collaboration. This marks Dyno’s second capsid licensed from its ...
Under a research collaboration first established in 2021, Astellas Pharma is moving to license a Dyno Therapeutics gene therapy vehicle—an adeno-associated virus (AAV) capsid engineered for ...
Non-human primate study results demonstrate improvements in skeletal and cardiac muscle delivery efficacy, safety potential, human translatability, and manufacturability over prior AAV capsids ...
WATERTOWN, Mass.--(BUSINESS WIRE)--Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to solve the grand challenge of in vivo gene delivery, today announced ...
-- Agreement leverages Sarepta’s leadership in gene therapy for neuromuscular and cardiovascular diseases and Dyno’s CapsidMap artificial intelligence platform to design AAV vectors -- CAMBRIDGE, Mass ...
- Dyno receives $18 million upfront and is eligible for milestone and royalty payments potentially exceeding $1.6 billion - TOKYO and CAMBRIDGE, Mass, Dec. 1, 2021 /PRNewswire/ -- Astellas Pharma Inc.
The MarketWatch News Department was not involved in the creation of this content. -- Dyno to receive a $15 million fee plus potential milestone and royalty payments under terms established in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results